Part 7- Treating T3 Deficiency, The Evidence You Need
Objectives
Upon completion of this workshop, the healthcare professional will be able to:
- Recognize that suppressed TSH levels from exogenous thyroid administration does not result in harm, based on literature review and meta-analysis.
- Recall that a suppressed TSH, along with elevated thyroid hormone produced endogenously, is associated with harm but that is only with Graves’ disease.
- Discuss why suppressed levels of TSH with exogenous administration will not result in the same harm as seen with Graves’ disease.
- Demonstrate that the harm of Graves’ disease should not be extrapolated to suppressing TSH with exogenous thyroid hormone administration.
- Review the studies demonstrating the harm of autoimmune Graves’ disease, even after definitive treatment and normalization of thyroid hormone.
- Finally, contrast the persistent harm of Graves’ disease from the autoimmune disease that should not be extrapolated to TSH suppression from exogenous thyroid administration
Instructor
Neal Rouzier, MD
Faculty Chairman
Accreditation
In support of improving patient care, this activity has been planned and implemented by The Foundation for Care Management (FCM) and Worldlink Medical. FCM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This program is approved for 1.0 AMA Category 1 Credits.
This program is approved for 1.0 Nursing Contact hour of Education.
Enrollment Options
Enroll today with a Premium Membership for $495/year, for access to THIS course and:
- All 1 Hour Accredited Courses (28+ more added monthly)
- All upcoming Accredited Monthly Webinars
- All upcoming Journal Clubs AND Journal Club Library
- EBSCOhost – research articles for the BHRT Workshop Series and to support your own evidence based studies!
